Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Ivosidenib (AG-120) and enasidenib (AG-221) are targeted oral inhibitors of the mutant isocitrate dehydrogenase (mIDH) 1 and 2 enzymes, respectively. Given their effectiveness as single agents in mIDH1/2 relapsed or refractory acute myeloid leukemia (AML), this phase 1 study evaluated the safety and...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Blood
Главные авторы: Stein, Eytan M., DiNardo, Courtney D., Fathi, Amir T., Mims, Alice S., Pratz, Keith W., Savona, Michael R., Stein, Anthony S., Stone, Richard M., Winer, Eric S., Seet, Christopher S., Döhner, Hartmut, Pollyea, Daniel A., McCloskey, James K., Odenike, Olatoyosi, Löwenberg, Bob, Ossenkoppele, Gert J., Patel, Prapti A., Roshal, Mikhail, Frattini, Mark G., Lersch, Frederik, Franovic, Aleksandra, Nabhan, Salah, Fan, Bin, Choe, Sung, Wang, Hongfang, Wu, Bin, Hua, Lei, Almon, Caroline, Cooper, Michael, Kantarjian, Hagop M., Tallman, Martin S.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2021
Предметы:
Myeloid Neoplasia
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8020270/
https://ncbi.nlm.nih.gov/pubmed/33024987
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020007233
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы